Teva Pharmaceutical’s bid to bring a new migraine drug to the market faces a possible delay due to manufacturing problems found with one of the company’s partners, and observers are skeptical about whether Teva will be able to get it over the finish line.
The FDA was set to issue a decision about Teva’s (NYSE: TEVA) injectable migraine drug, fremanezumab, by June 16. But the Israel-based drug maker disclosed Thursday that Celltrion, the manufacturer of the active ingredient for the drug, received an FDA warning letter about unspecified issues at a site in South Korea where it makes the drug… Read more »
UNDERWRITERS AND PARTNERS